A Pilot Trial of Pioglitazone HCl and Tretinoin in ALS: Cerebrospinal Fluid Biomarkers to Monitor Drug Efficacy and Predict Rate of Disease Progression
Objectives. To determine if therapy with pioglitazone HCl and tretinoin could slow disease progression in patients with ALS. Levels of tau and pNFH in the cerebrospinal fluid were measured to see if they could serve as prognostic indicators. Methods. 27 subjects on stable doses of riluzole were enro...
Saved in:
Main Authors: | Todd D. Levine, Robert Bowser, Nicole C. Hank, Stephen Gately, Dietrich Stephan, David S. Saperstein, Kendall Van Keuren-Jensen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Neurology Research International |
Online Access: | http://dx.doi.org/10.1155/2012/582075 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Serum and Cerebrospinal Fluid Cytokine Biomarkers for Diagnosis of Multiple Sclerosis
by: Ekaterina Martynova, et al.
Published: (2020-01-01) -
Cerebrospinal fluid metabolites as potential biomarkers for epilepsy: Insights from genome‐wide association studies
by: Zhenxiang Zhao, et al.
Published: (2025-02-01) -
Changes in Cerebrospinal Fluid Biomarkers in Human Herpesvirus-6-Associated Acute Encephalopathy/Febrile Seizures
by: Naoyuki Tanuma, et al.
Published: (2014-01-01) -
Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson’s Disease: A Meta-Analysis
by: Dan Xie, et al.
Published: (2021-01-01) -
β-synuclein in cerebrospinal fluid as a potential biomarker for distinguishing human prion diseases from Alzheimer’s and Parkinson’s disease
by: Bing Xu, et al.
Published: (2025-02-01)